Song C, Lin Y, Cai C, Tao K, et al. LOXL2 reduces susceptibility to PARP inhibitors by promoting super-enhancer-regulated DNA damage repair in high-grade serous ovarian cancer. Oncogene 2025 May 31. doi: 10.1038/s41388-025-03466.
PMID: 40447755